NCT00036387 – A Randomized, Double-blind Trial of the Safety of Anti-TNF Chimeric Monoclonal Antibody (Infliximab) in Combination With Methotrexate Compared to Methotrexate Alone in Patients With Rheumatoid Arthritis on Standard Disease-modifying Anti-Rheumatic Drug Posted on September 10, 2018 by tsuperadmin -
NCT00207740 – A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Evaluating the Efficacy and Safety of CNTO 148 Administered Subcutaneously in Symptomatic Subjects With Severe Persistent Asthma Posted on August 6, 2018 by tsuperadmin -
NCT01962974 – A Golimumab Phase 3b, Multicenter, Assessment of Intravenous Efficacy in Rheumatoid Arthritis Subjects Who Have Diminished Disease Control Despite Treatment With Infliximab (REMICADE®) Posted on August 6, 2018 by tsuperadmin -
NCT01988961 – A Study to Evaluate the Accuracy of a Subset of the Length-109 Probe Set Panel (a Genetic Test) in Predicting Response to Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis Posted on August 6, 2018 by tsuperadmin -
NCT01863771 – A Safety and Effectiveness Study of Golimumab in Japanese Patients With Moderately to Severely Active Ulcerative Colitis Posted on August 6, 2018 by tsuperadmin -
NCT01004432 – Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA) Posted on August 6, 2018 by tsuperadmin -
NCT02181673 – A Study of Golimumab in Participants With Active Psoriatic Arthritis Posted on August 6, 2018 by tsuperadmin -
NCT01230827 – A Study of the Safety and Efficacy of CNTO 148 (Golimumab) in Children With Juvenile Idiopathic Arthritis (JIA) and Multiple Joint Involvement Who Have Poor Response to Methotrexate (GO KIDS) Posted on August 6, 2018 by tsuperadmin -
NCT00265122 – A Multicenter, Randomized, Phase 2a Study of Human Monoclonal Antibody to IL-12p40 (CNTO 1275) in Subjects With Moderately to Severely Active Crohn’s Disease Posted on July 3, 2018 by tsuperadmin -
NCT00488774 – A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis Posted on June 7, 2018 by tsuperadmin -
The YODA Project